A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
Zai Lab (Shanghai) Co., Ltd.
Summary
A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
Description
This is an open-label, multiple-center, phase 1b/2 study of ZL-1310 in selected solid tumors. ZL-1310 will be administered intravenously at 1.6 mg/kg every 21 days. Primary objectives include safety evaluation and confirmed objective response rate by blinded independent central review
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Signed informed consent * Adult men and women ≥18 years of age * Participants must have histologically confirmed, locally advanced or metastatic NeuroEndocrine Carcionomas (NEC) * Participants must be willing to undergo a tumor biopsy or must provide archived tumor tissue sample * Participants must have at least one measurable target lesion as defined by RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy ≥ 3 months Exclusion Criteria: * Participants with another known malignancy that is progressing or requires active…
Interventions
- DrugZL-1310
drug ZL-1310
Locations (23)
- University of California San Francisco/Helen Diller Family Comprehensive Cancer CenterSan Francisco, California
- OSF St. Francis Medical CenterPeoria, Illinois
- Karmanos Cancer CenterDetroit, Michigan
- Memorial Sloan-Kettering Cancer CenterNew York, New York
- University Hospitals Cleveland Medical CenterCleveland, Ohio
- Fox Chase Cancer CenterPhiladelphia, Pennsylvania